Locations:
Search IconSearch
June 9, 2021/Cancer/Tumor Oncology

Adjuvant Pembrolizumab Improves Relapse-Free Survival in Patients with High-Risk Resected Melanoma

Overall survival benefit not established

Metastatic melanoma cells. Image source: National Cancer Institute

The immune checkpoint inhibitor and anti-PD-L1 monoclonal antibody pembrolizumab improves relapse-free survival (RFS) but not overall survival (OS) when compared with other adjuvant treatments for patients with high-risk resected melanoma, according to the final analysis of the SWOG S1401 phase 3 randomized trial. Researchers presented the analysis at the American Society of Clinical Oncology’s 2021 annual meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Two FDA-approved adjuvant therapies are available to patients with advanced high-risk resected melanoma — high-dose interferon and high-dose ipilimumab — but their therapeutic index is modest given the high toxicity of the treatments. “The S1404 study has been looking at pembrolizumab as a potential adjuvant option for these patients because it has low toxicity overall and a good response rate in patients with stage IV disease,” notes Pauline Funchain, MD, staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center and coauthor of the study. “This analysis confirms that pembrolizumab can help patients stay disease free for longer.”

Study design

Adult patients with stages IIIA(N2), IIIB, IIIC and IV (M1a, b, c) but without brain metastases were eligible. All patients who entered the study had surgically resected melanoma, including lymph node dissection for positive disease, as well as no prior exposure to PD-L1 blockade, ipilimumab or interferon.

Patients were enrolled between 2015 and 2017 and separated into two treatment arms based on stage, PD-L1 staining status and intended control arm. Patients were randomized 1:1 to the control arm or experimental arm. The control arm treatment included interferon alfa-2p 20MU/m2 IV days 1-5, weeks 1-4, followed by 10 MU/m2/d SC days 1, 3 and 5, weeks 5-52 (N = 190) or ipilimumab 10 mg/kg IV every three weeks for four doses, then every 12 weeks for up to three years (N = 465). Patients in the experimental arm received pembrolizumab 200 mg IV every three weeks for a year (N = 648).

Advertisement

Researchers focused on three primary comparisons in the per-protocol final analysis: RFS and OS among all patients, as well as OS among patients with PD-L1 positive status. Of the 1,345 patients randomized, 11% had AJCC7 stage IIA(N2), 49% were IIIB, 34% were IIIC and 6% were stage IV.

The pembrolizumab group experienced a significant improvement in RFS compared with the control group (HR 0.740, 99.618% CI, 0.571 to 0.958). Neither the patients with PD-L1 positive baseline biopsies nor the overall patient population experienced a significant improvement in OS (HR 0.847, 96.3% CI, 0.622 to 1.297), and HR 0.883, 97.8% CI, 0.604 to 1.291), respectively. Patients in the pembrolizumab arm experienced significantly fewer grade 3 adverse events than patients in the control arm.

Clinical impact

The lack of OS benefit of adjuvant pembrolizumab raises questions about treatment timing for patients with high-risk resected melanoma.

“The data on relapse-free survival and toxicity are encouraging. Every additional scan that is free of disease is a big deal for a patient,” says Dr. Funchain. “On the other hand, these data provide some reassurance for patients who may be hesitant for personal or medical reasons to take on adjuvant immunotherapy. At least in in the short term, we see little to no detriment in terms of survival. But the findings regarding overall survival truly need longer follow up in order to fully understand the long-term benefits of adjuvant therapy.”

Advertisement

Related Articles

22-CNR-IV-Drip-CQD-Hero-650×450-1
April 20, 2022/Cancer/Tumor Oncology
Combination Chemo-Immunotherapy Appears to Improve Outcomes in Muscle-Invasive Bladder Cancer

New results from the BLASST-1 trial show increases in downstaging and relapse-free survival

Mammary carcinoma with lobular features. Breast cancer
April 12, 2022/Cancer/Tumor Oncology
MRI May Be Best Tool for Tumor Staging and Detecting Bilateral Disease in Invasive Lobular Carcinoma

Study highlights value of preoperative imaging to guide surgical decision-making

rt-breast_650x450
July 1, 2021/Cancer/Tumor Oncology
Designing an Optimal Breast Cancer Radiation Protocol

How a novel tissue marker makes a difference

PrimaryPulmonaryCarcinoid
June 29, 2021/Cancer/Tumor Oncology
Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

650×450-bladder
May 24, 2021/Cancer/Tumor Oncology
Combination Maintenance Therapy in Metastatic Urothelial Cancer

In search of improved outcomes for patients

650×450-Prostate-GettyImages-580120508_New Header_17-URL-680
May 12, 2021/Cancer/Tumor Oncology
Innovations in Prostate Cancer Care

An overview of our leading-edge diagnostics and therapeutics

Ad